



Board of Directors – 2022 Operational Summary

Date	Resolutions
2022/01/21	<ul style="list-style-type: none">• Proposal to renew loan agreement with financial institution.• Proposal to provide a loan guarantee of NT\$50 million to Bora Health Inc. (formerly named: Yuta Health Co., Ltd.), a company that is 100% owned by the Company.• Proposal to formulate the record date of cash capital increase for the Company's 2018 employee stock warrant exercised on 2021 Q4.• Amendment to the Company's 2021 First Employee Stock Warrant Plan.• Proposal to distribute 2021 First Employee Stock Warrant to manager.• Proposal to distribute 2021 First Employee Stock Warrant to non-manager.• Formulate the Company's 2022 Stock Repurchase and Transfer to Employee Program.• To purchase the Company's treasury stock.
2022/03/09	<ul style="list-style-type: none">• The Company's 2021 Statement on Internal Control.• The Company to change CPA due to accounting firm's internal CPA rotation.• Evaluation on the Company CPA's independence.• 2021 Business Operation Report and Financial Statements.• 2021 Surplus Distribution in the form of Cash Dividend.• Distribute new shares for capital increase by earnings.• Amendment to the Articles of Incorporation.• Proposal to renew loan agreement with financial institution.• Proposal to provide a loan guarantee of NT 30 million to Bora Pharmaceuticals Laboratories Inc., a company that is 100% owned by the Company.• Proposal to provide a loan guarantee of NT 40 million to Bora Health Inc., a company that is 100% owned by the Company.• Proposal to provide a loan guarantee of NT 60 million to Bora Health Inc., a company that is 100% owned by the Company.• Proposal to provide a loan guarantee to Bora Health Inc., a company that is 100% owned by the Company.• Amendment to the Procedure for Lending Funds to Other Party, Procedure for Endorsement and Guarantee, Procedure for Acquiring and Disposing Assets, Procedure for Engaging in Financial Derivative Transaction and others.• Amendment to the internal control system, authorization table, authorization table management guideline, guideline on the transaction with the Company's related party, monitor and management on the Company's subsidiary, internal control implementation guideline, and others.

	<ul style="list-style-type: none"> • The Company's Board of Director's resolution on approving the Company's subsidiary Bora Health Inc.'s future over the counter or listed plan. • The Company's Board of Director's resolution on 2022 stockholder meeting and related item. • To announce the Company set up the Sustainable Development Committee and its committee member. • Proposal on the Company's 100% owned subsidiary Bora Pharmaceutical Service Inc. to purchase operating asset. • 2021 year-end performance bonus distribution for the Company's managerial personnel. • Proposal to appoint the Company's 100% owned subsidiary Bora Health Inc.'s manager Henry Kuo as the Company's managerial personnel. • Appointment on the Company's accounting manager. • 2021 Employees' and Directors' Compensation. • Promotion on the Company's finance manager, corporate governance manager and deputy spokesman to vice president. • 2021 Directors compensation distribution detail. • 2021 employee remuneration distribution detail for managerial personnel. • Appointment on the Company's human resource manager.
2022/04/11	<ul style="list-style-type: none"> • Proposal to spin off the Company's pharmaceuticals department to the Company's 100% owned subsidiary. • Proposal to add report item for 2022 stockholder's meeting • Proposal to renew loan agreement with financial institution. • Proposal to provide a loan guarantee of NT 307 million to Bora Pharmaceuticals Laboratories Inc., a company that is 100% owned by the Company. • Proposal to provide a loan guarantee of NT 30 million to Bora Health Inc., a company that is 100% owned by the Company. • Proposal to formulate the record date of cash capital increase for the Company's 2018 employee stock warrant exercised on 2022 Q1. • Proposal to revise the Company's 2022 internal audit plan. • Proposal to increase cash capital of NT \$400 million for the 100% owned subsidiary Bora Pharmaceutical Laboratories Inc. • The Company's managerial personnel 2022 remuneration raise 10. Amendment to the Procedure for Acquiring and Disposing Assets.
2022/05/10	<ul style="list-style-type: none"> • Proposal to revise the Company's 2022 internal audit plan. • Revise the "Sustainable Development Committee Organization Rule" • The Company's Board of Director's resolution on the Company's 2022 Q1 financial statement. • Proposal to renew loan agreement with financial institution. • Proposal to issue the Company's 2021 employee stock warrants to manager.



	<ul style="list-style-type: none"> • Proposal to issue the Company's 2021 employee stock warrants to non-manager. • Proposal to provide loan guarantee amounted to NTD 360 million to 100% owned subsidiary Bora Biologics Co., Ltd. • Proposal for subsidiary Bora Biologics Co., Ltd. to acquire Eden Biologics, Inc.'s equipment, employee, and CDMO business which located in HsinChu Science Park. • Proposal to lend 100% owned subsidiary Bora Biologics Co., Ltd.
2022/06/14	<ul style="list-style-type: none"> • Proposal to participate the cash capital increase of the 100% owned subsidiary Bora Biologics Co., Ltd. for NTD 1.68 billion. • Proposal on issuing the Company's 2nd domestic unsecured convertible corporate bonds. • Proposal to renew loan agreement with financial institution. • Proposal to continue to provide a loan guarantee to Bora Health Inc., a company that is 100% owned by the Company. • Proposal to continue to provide a loan guarantee to Bora. Pharmaceutical Laboratories Inc., a company that is 100% owned by the Company. • For strategic investment purpose, the Company's proposal to acquire 100% of stock of TWi Pharmaceuticals, Inc. • The Company's Board of Director's resolution on 2022 first extraordinary stockholder meeting.
2022/08/12	<ul style="list-style-type: none"> • The Company's Board of Director's resolution on the Company's 2022 Q2 financial statement. • Proposal to distribute the Company's earnings for the first half of 2022. • The Company's Board of Director's resolution on ex-rights date and the price adjustment for the employee stock warrant. • Proposal to renew loan agreement with financial institution. • Proposal to sign short term Bridge Loan with financial institution and the execution of syndicated loan. • Proposal to issue the Company's 2021 employee stock warrants to non-manager. • Proposal to issue project bonus for manager. • Proposal for the Company's guarantee annual remuneration.
2022/09/28	<ul style="list-style-type: none"> • The Company and TWi Pharmaceuticals, Inc. (Twi) jointly sign a syndicated loan and appoint China Trust Commercial Bank Co as the management bank.
2022/11/14	<ul style="list-style-type: none"> • The Company's Board of Director's resolution on the Company's 2022 Q3 financial statement • Amendment to the Company's "Rules and procedures for the Board of Director Meeting". • Amendment to the Company's "Internal material information processing and procedures for preventing insider trading".



	<ul style="list-style-type: none">• Amendment to the Company's "Best Practice for Sustainable Development".• Proposal to renew loan agreement with financial institution.• Appointment of Frank Chen, vice president for the Company's information management department, to the Company's manager.• Proposal to issue the Company's 2021 first employee stock warrants to manager.• Proposal to issue the Company's 2021 first employee stock warrants to non-manager.• Proposal to issue Bora Biologics' 2022 first employee stock warrants to the Company's manager.
2022/12/02	<ul style="list-style-type: none">• The Company's 2023 operating plan.• The Company's 2023 budget.• The Company's 2023 internal audit plan.• Amendment to the Company's "Corporate Governance Best Practice Principles".• Proposal to renew loan agreement with financial institution.• The Company's 2022 year end bonus for manager.• Transfer the treasury stock to non-manager in accordance to "2022 Stock Repurchase and Transfer to Employee Program" .